arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Forte Biosciences, Inc.

FBRX Health Care Biotechnology: Pharmaceutical Preparations
$76.99
0.0% Today
as of Oct 23, 16:48 ET
Open
$76.97
High
$77.00
Low
$76.96
Volume
$1M
Avg Vol
$1M
Mkt Cap
$1.6B
P/E (TTM)
—
Beta
—
52w High
$77.20
52w Low
$10.11
Div Yield
—
Shares Out
$20M

Recent Press Releases & News last 60 days · 3 items

Aug 27 · 17:08 Simply Wall St.
Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition
Aug 27 · 13:09 MT Newswires
Argenx Completes Acquisition of Forte Biosciences
Aug 27 · 12:50 PR GlobeNewswire
argenx Completes Acquisition of Forte Biosciences, Inc.

FBRX earnings at a glance

The options market is pricing a move of about ±6.5% after the report, a range of roughly $71.99 to $81.99 from today's $76.99. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±5.6% on average; after the most recent report on May 11, 2026 it moved +8.2%. That means options currently expect more movement than FBRX has typically delivered. FBRX beat the consensus EPS estimate in 1 of its last 2 reported quarters. Implied volatility is currently 32%. The share price of $76.99 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$10
$77
100% of range
Avg surprise (last 2)
-16.6%
Avg reaction (last 2)
+5.6%
100% positive
Latest IV / EM
32%
EM ±6.5% · $75 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-6.78$-5.17$-3.55$-1.94$-0.32 Actual $-0.32Actual $-0.42Actual $-6.57Actual $-4.03Actual $-6.78Actual $-4.54Actual $-1.37Est $-0.89Actual $-0.96Est $-1.21Actual $-0.99Actual $-1.24Actual $-0.97 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-23M$-20M$-16M$-12M$-9M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.97 — — — — financials
Mon May 11, 2026Mar/2026 $-1.24 — — +9.5% +8.2% earnings
Tue Sep 30, 2025Sep 2025 $-0.99 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.96 $-1.21 +20.7% — — earnings
Thu May 15, 2025Mar/2025 $-1.37 $-0.89 -53.9% — +3.0% earnings
Mon Sep 30, 2024Sep 2024 $-4.54 — — — — financials
Sun Jun 30, 2024Jun 2024 $-6.78 — — — — financials
Sun Mar 31, 2024Mar 2024 $-4.03 — — — — financials
Sat Sep 30, 2023Sep 2023 $-6.57 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.42 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.32 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-25M$-22M—$-18M$-12M$-16M—$-9M
Net income$-23M$-22M—$-18M$-11M$-16M—$-8M
EPS (diluted)$-0.97$-1.24—$-0.99$-0.96$-1.37—$-4.54

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$50M$58M$77M$93M$106M$46M$22M$16M
Inventory————————
Total current assets$203M$65M$81M$95M$108M$47M$61M$18M
Total assets$206M$67M$83M$97M$108M$47M$62M$18M
Long-term debt————————
Total liabilities$22M$25M$22M—————
Total equity$184M$42M$61M$84M$99M$38M$52M$9M

Implied volatility — last 90 days

1%124%247%370%493% Jun 07 — IV 273% · EM ±37.8%Jun 08 — IV 254% · EM ±33.5%Jun 09 — IV 245% · EM ±30.7%Jun 10 — IV 274% · EM ±32.4%Jun 11 — IV 272% · EM ±30.0%Jun 12 — IV 320% · EM ±32.7%Jun 15 — IV 276% · EM ±19.9%Jun 16 — IV 494% · EM ±29.2%Jun 19 — IV 195% · EM ±43.0%Jun 22 — IV 195% · EM ±40.8%Jun 23 — IV 193% · EM ±39.4%Jun 24 — IV 184% · EM ±36.8%Jun 25 — IV 188% · EM ±36.9%Jun 26 — IV 209% · EM ±40.1%Jun 29 — IV 228% · EM ±40.3%Jun 30 — IV 223% · EM ±38.4%Jul 01 — IV 264% · EM ±44.1%Jul 02 — IV 241% · EM ±39.0%Jul 03 — IV 249% · EM ±39.0%Jul 06 — IV 275% · EM ±38.1%Jul 07 — IV 265% · EM ±34.9%Jul 08 — IV 279% · EM ±35.0%Jul 09 — IV 146% · EM ±17.3%Jul 10 — IV 169% · EM ±18.7%Jul 13 — IV 176% · EM ±14.7%Jul 14 — IV 187% · EM ±13.5%Jul 15 — IV 188% · EM ±11.1%Jul 16 — IV 282% · EM ±11.8%Jul 20 — IV 169% · EM ±40.0%Jul 21 — IV 180% · EM ±41.9%Jul 22 — IV 184% · EM ±42.0%Jul 23 — IV 199% · EM ±44.7%Jul 24 — IV 196% · EM ±43.4%Jul 27 — IV 42% · EM ±8.8%Jul 28 — IV 8% · EM ±1.7%Jul 29 — IV 12% · EM ±2.4%Jul 30 — IV 3% · EM ±0.6%Jul 31 — IV 3% · EM ±0.5%Aug 03 — IV 3% · EM ±0.5%Aug 04 — IV 2% · EM ±0.3%Aug 05 — IV 2% · EM ±0.3%Aug 06 — IV 2% · EM ±0.4%Aug 07 — IV 3% · EM ±0.5%Aug 10 — IV 2% · EM ±0.3%Aug 25 — IV 34% · EM ±7.0%Aug 26 — IV 32% · EM ±6.5%

Sector peers

QURE
uniQure N.V.
$1.6B $22.43-1.1%
CMPS
COMPASS Pathways Plc
$1.6B $11.18-5.6%
OCUL
Ocular Therapeutix, Inc.
$1.6B $6.50+0.3%
STOK
Stoke Therapeutics, Inc.
$1.6B $25.04-2.5%
PAHC
Phibro Animal Health Corporation
$1.5B $38.80-1.1%
SNDX
Syndax Pharmaceuticals, Inc.
$1.5B $13.40+1.9%

FBRX earnings FAQ

What is FBRX's expected move for earnings?

Options currently price a move of about ±6.5%, or $5.00 per share either way from $76.99.

How does FBRX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±5.6%, up 2 times and down 0 times.

What is FBRX's implied volatility?

FBRX's at-the-money implied volatility is about 32% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in